Information  X 
Enter a valid email address

VASTox plc (SUMM)

  Print   

Wednesday 27 June, 2007

VASTox plc

Re Agreement

VASTox plc
27 June 2007

                                   VASTox plc
                          ('VASTox' or 'the Company')


   VASTOX ANNOUNCES SIGNIFICANT PROGRESS IN PHARMACEUTICAL SERVICES BUSINESS


  • Pilot screening deals signed in zebrafish platform with top tier
    pharmaceutical companies worth in excess of €300,000

  • Completion of carbohydrate chemistry GMP clinical scale-up facility


Oxford, UK, 27 June 2007 - VASTox plc (AIM: VOX), a leading UK biotechnology
company, announces that it has entered into a series of pilot screening
agreements with major pharmaceutical companies, including Merck KGaA, Johnson &
Johnson (Pharmaceutical Research & Development, Belgium) and Servier.  Together,
the deals are worth in excess of €300,000 in service revenues to VASTox during
2007.


VASTox will use its market-leading zebrafish technology platform to blind-screen
selections of known compounds for safety and toxicity to validate to its clients
how this technology can predict unwanted side effects. It is the Company's aim
to develop these relationships into higher-value, longer-term partnerships.


A strategy of internal growth and focused acquisitions over the past 18 months
has seen VASTox assemble the most advanced and extensive zebrafish technology
platform in the world.  This versatile organism is proving highly valuable in
drug discovery because it can be used to predict the safety of potential drug
candidates as well as to develop a wide range of models of human diseases
including neuro-disorders and regenerative medicine, therapeutic areas in which
VASTox has drug discovery programmes.


Completion of GMP Facility

VASTox also announces today that it has completed, on-time and on-budget, the
construction of its GMP facility located at its subsidiary company, Dextra
Laboratories, which specialises in carbohydrate chemistry.  The GMP facility
will allow VASTox to produce material in sufficient quantities for use in human
clinical trials up to the Phase II stage of clinical development.


In order to ensure the facility is fully GMP compliant, VASTox will perform a
test run to produce material for one of its own drug discovery programmes with
the facility receiving its first fee-paying client by the end of July 2007.


Steven Lee, PhD, CEO of VASTox commented: 'The zebrafish is emerging as a
valuable and powerful tool within drug discovery and VASTox is the world's
leader in the use of this organism.  The signing of these pilot deals means
VASTox has now worked with seven of the ten largest pharmaceutical companies,
which provides continued recognition of our technology and an opportunity to
further validate this exciting technology platform.'


He added: 'The completion of the GMP laboratory is a key milestone for our
pharmaceutical service offering.  Carbohydrate chemistry is becoming
increasingly important in the search for and development of effective new drugs
and our Dextra subsidiary is already established as a leading force in this
field.  With GMP accreditation, VASTox can now offer its partners and customers
the highest quality carbohydrate chemistry services from discovery through to
clinical development.'


                                    - ends -


For more information please contact:


VASTox

Steven Lee, PhD, Chief Executive Officer                 Tel: +44 (0)1235 443951

Darren Millington, ACMA, Chief Financial Officer


Citigate Dewe Rogerson

Mark Swallow / David Dible / Valerie Auffray            Tel: +44 (0)207 638 9571


Evolution Securities

Tim Worlledge / Bobbie Hilliam / Neil Elliot            Tel: +44 (0)207 071 4300


About VASTox plc


VASTox is a leading UK biotechnology company that discovers and develops
proprietary new drugs. The Company's internal drug development programmes are
underpinned by its advanced chemistry and drug screening (chemical genomics)
technology platforms, which it also provides on a collaborative or
fee-for-service basis to the pharmaceutical industry.


VASTox has a broad range of drug discovery programmes in the clinical,
pre-clinical and discovery stages of development, which target serious diseases
with a high unmet medical need. These therapeutic areas include neuro-disorders
(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,
oncology and regenerative medicines.


VASTox's in-house drug development capabilities combine world-class expertise in
both medicinal and carbohydrate chemistry with high-volume, high-content
screening using its proprietary zebrafish and fruitfly technologies (chemical
genomics). These whole organism screens have the potential to dramatically
decrease the time and cost of drug discovery and development by delivering data
that are highly predictive of the efficacy and toxicity of potential drug
compounds in humans.


The company listed on the AIM market of the London Stock Exchange in October
2004 - symbol: VOX


Further information about the company is available at www.vastox.com


This document contains 'forward-looking statements' within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as 'anticipates', 'intends', 'plans',
'seeks', 'believes', 'estimates', 'expects' and similar references to future
periods, or by the inclusion of forecasts or projections.


Forward-looking statements are based on the Company's current expectations and
assumptions regarding our business, the economy and other future conditions.
Because forward-looking statements relate to the future, by their nature, they
are subject to inherent uncertainties, risks and changes in circumstances that
are difficult to predict. The Company's actual results may differ materially
from those contemplated by the forward-looking statements. The Company cautions
you therefore that you should not rely on any of these forward-looking
statements as statements of historical fact or as guarantees or assurances of
future performance. Important factors that could cause actual results to differ
materially from those in the forward-looking statements and regional, national,
global political, economic, business, competitive, market and regulatory
conditions.




                      This information is provided by RNS
            The company news service from the London Stock Exchange        ROKAKDFBKDCAB                                                                                                                                                                                                                                                  

a d v e r t i s e m e n t